Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iridex (IRIX) Cash from Discontinued Operations (2011 - 2013)

Iridex's quarterly Cash from Discontinued Operations came in at 510000.0 in Q2 2013, up 112.55% year-on-year from 239940.94 in Q2 2012, and up 111.29% quarter-over-quarter from 4519000.0 in Q4 2012.

Iridex has reported Cash from Discontinued Operations for 3 years, with the latest figure at 510000.0 in Q2 2013.

  • For the quarter ending Q2 2013, Cash from Discontinued Operations rose 112.55% year-over-year to 510000.0; the trailing twelve-month figure through Dec 2013 stood at 510000.0 (down 26.62% YoY), and the FY2013 full-year result was 510000.0, down 26.62% from the prior year.
  • Cash from Discontinued Operations for Q2 2013 stood at 510000.0, up from 4519000.0 in the prior quarter.
  • The five-year high for Cash from Discontinued Operations was 4809000.0 in Q3 2012, with the low at 4519000.0 in Q4 2012.
  • Average Cash from Discontinued Operations over 3 years is 222333.33, with a median of 176000.0 recorded in 2011.
  • Peak annual rise in Cash from Discontinued Operations reached 9918.75% in 2012, while the deepest fall reached 2667.61% in 2012.
  • Tracing IRIX's Cash from Discontinued Operations over 3 years: stood at 176000.0 in 2011, then tumbled by 2667.61% to 4519000.0 in 2012, then jumped by 111.29% to 510000.0 in 2013.
  • The last three Cash from Discontinued Operations figures came in at 510000.0 (Q2 2013), 4519000.0 (Q4 2012), and 4809000.0 (Q3 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Iridex 18.87 Mn 14.27 Mn 4.74 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 29, 2013 510,000.00
Jun 29, 2013 510,000.00
Dec 29, 2012 4.82 Mn
Dec 29, 2012 4.82 Mn
Sep 29, 2012 -4.53 Mn
Sep 29, 2012 -4.53 Mn
Jun 30, 2012 5.27 Mn
Jun 30, 2012 5.27 Mn
Mar 31, 2012 -199,000.00
Mar 31, 2012 -199,000.00
Dec 31, 2011 177,000.00
Dec 31, 2011 177,000.00
Oct 1, 2011 48,000.00
Oct 1, 2011 48,000.00
Jul 2, 2011 -264,000.00
Jul 2, 2011 -264,000.00
Apr 2, 2011 836,000.00
Apr 2, 2011 836,000.00